Bio Pharma Dive
OCTOBER 8, 2024
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
Pharmaceutical Technology
OCTOBER 8, 2024
The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and cirrhosis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 8, 2024
“The time to re-enter the RNAi revolution is now,” said Robert Nelso=en, the managing director of Arch, which led the Series A funding round for City Therapeutics.
Pharmaceutical Technology
OCTOBER 8, 2024
Bayer has entered a collaboration with MOMA Therapeutics in which the two companies will advance a small molecule oncology programme.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
OCTOBER 8, 2024
After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.
Fierce Pharma
OCTOBER 8, 2024
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.” In declaring the end of the shortage, the FDA has halted the ability of compounding pharmacies to manufacture the in-demand products.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Rethinking Clinical Trials
OCTOBER 8, 2024
The Health Care Systems Research Network (HCSRN) is accepting abstract submissions and panel proposals for its 2025 Annual Conference until December 9, 2024. This year’s meeting will be held in St. Louis, Missouri, from April 8 to 10, 2025. Information about conference registration, preconference workshops, and accommodations is also available. Early-bird registration is open through February 21.
Pharmaceutical Technology
OCTOBER 8, 2024
The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung cancer.
Pharma Times
OCTOBER 8, 2024
Real-world studies show effectiveness of mogamulizumab in routine practice
Pharmaceutical Technology
OCTOBER 8, 2024
Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.
Fierce Pharma
OCTOBER 8, 2024
Editor's Note: Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub in Tampa, Florida, in 2021—is setting out to bolster emergency services, pool donations and ease medical supply needs as Hurricane Milton touches down this week.
Pharmaceutical Technology
OCTOBER 8, 2024
The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies.
Drug Patent Watch
OCTOBER 8, 2024
A recent study published in Drug Discovery Today highlights the potential of artificial intelligence (AI) in revolutionizing drug discovery and development processes[1]. The research, conducted by a team from the University of Cambridge and AstraZeneca, explores how AI can be leveraged to enhance various aspects of pharmaceutical research, from target identification to clinical trials.
Pharmaceutical Technology
OCTOBER 8, 2024
ViiV Healthcare has announced plans to triple annual supply of long-acting cabotegravir for HIV PrEP to at least two million doses.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 8, 2024
Stay updated on the latest insights from EASD 2024 with a comprehensive breakdown of key themes, topics, and influencers. Learn more about the essential information you need to know.
Pharmaceutical Technology
OCTOBER 8, 2024
Innovent Biologics and ASK Pharm have signed a strategic partnership for the commercialisation of limertinib for the treatment of lung cancer.
Fierce Pharma
OCTOBER 8, 2024
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a new positive readout can return Keytruda to glory in head and neck cancer about two years after a prior failure.
pharmaphorum
OCTOBER 8, 2024
Collaboration is essential for the future of healthcare, and events play a pivotal role in fostering it. Learn how collaboration can drive innovation in healthcare through impactful events.
Fierce Pharma
OCTOBER 8, 2024
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case for its first-to-market respiratory syncytial virus (RSV) shot Arexvy. | GSK on Tuesday unveiled fresh data from the late-stage AReSVi-006 study of Arexvy in RSV-triggered lower respiratory tract disease in older adults over the span of three full RSV seasons.
pharmaphorum
OCTOBER 8, 2024
Discover the latest advancements in weight loss treatments as developers race to create the next blockbuster solution. Stay informed about the cutting-edge options available.
Pharma Times
OCTOBER 8, 2024
AviadoBio to receive up to £1.
pharmaphorum
OCTOBER 8, 2024
How pharma companies can build mutually beneficial relationships with biotech and digital health start-ups Mike.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
OCTOBER 8, 2024
With the U.S. | The Congressional Budget Office found that only one out of the seven policies it reviewed would create notable reductions in prices. Still, that approach could affect market dynamics outside the U.S.
pharmaphorum
OCTOBER 8, 2024
Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS in draft guidance
BioPharma Reporter
OCTOBER 8, 2024
This yearâs Nobel prize in physiology or medicine has been awarded to Victor Ambros and Gary Ruvkun for their groundbreaking research on microRNA.
pharmaphorum
OCTOBER 8, 2024
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in early 2025.The stock rocketed 362% after the announcement, taking Scholar Rock's market cap above $2.7 billion, as analysts started to talk about a blockbuster sales opportunity for the selective myostatin inhibitor.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
OCTOBER 8, 2024
Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm is expanding its manufacturing capacity with undisclosed investments in its small molecule offerings.
pharmaphorum
OCTOBER 8, 2024
Biogen teams up with Talkiatry on telehealth programme for postpartum depression that could help drive sales of Zurzuvae
BioPharma Reporter
OCTOBER 8, 2024
The US Biosecure Act was passed by the House of Representatives in September and seems likely to become law.
pharmaphorum
OCTOBER 8, 2024
Astellas adds a gene therapy for frontotemporal dementia to its pipeline, via a $2.2bn+ option deal with UK biotech AviadoBio.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
162 
Let's personalize your content